Dr. Frank Agullo brings Motiva Preservé breast-preservation augmentation to Southwest Plastic Surgery

The aesthetic surgery sector is experiencing one of its most notable shifts in years, as Dr. Frank Agullo—widely known in the medical community as “Dr. WorldWide”—introduces the Motiva Preservé breast-preservation augmentation technique at Southwest Plastic Surgery in El Paso, Texas. This method, developed in collaboration with Establishment Labs Holdings Inc. (NASDAQ: ESTA), represents a new chapter in cosmetic enhancement by focusing on natural tissue preservation, smaller incisions, and a dramatically reduced recovery timeline.

The introduction of Motiva Preservé in the U.S. market carries significance beyond a single clinic launch. It underscores the growing convergence between surgical innovation, biotechnology, and patient-centric care models that emphasize both outcomes and quality of life. The approach builds upon Establishment Labs’ international reputation for safety and design innovation, with the company already recognized in Europe, Latin America, and Asia for reshaping expectations in the breast implant market.

Why is the Motiva Preservé method being described as a turning point in breast augmentation?

At its core, the Motiva Preservé technique challenges the long-standing norms of cosmetic surgery. Traditional breast augmentation often involves larger incisions, extensive muscle dissection, and post-surgical discomfort that can limit mobility for weeks. In contrast, Preservé employs a minimally invasive approach where implants are inserted through 2–3 cm incisions while preserving the pectoralis muscle and surrounding tissue.

This method is powered by Motiva Ergonomix implants, a lightweight, dynamic design that adapts naturally to body movement. Clinical data from Establishment Labs has highlighted that at the three-year follow-up point, there were no reported cases of lower-pole malposition, a complication that frequently affects patients in conventional augmentation surgeries. Such outcomes suggest that preserving the native tissue architecture not only enhances immediate cosmetic results but also contributes to long-term stability.

The implants themselves represent an important piece of biomedical innovation. Their lighter weight and reduced volume requirements—achieving the look of a 300–350cc implant with only 150–200cc—minimize strain on supporting ligaments. For patients, this translates into better comfort, reduced risk of long-term sagging, and enhanced durability of results.

How does the recovery process compare with traditional augmentation surgery timelines?

Perhaps the most transformative aspect for patients is the accelerated recovery. Procedures typically last about thirty minutes under light conscious sedation, significantly shorter than conventional augmentation timelines. Many patients at pilot centers have reportedly been able to dress themselves within an hour post-surgery and return to normal daily activities within one to two days. Gym workouts can often be resumed within just a few days, compared with weeks of restricted movement associated with older methods.

By preserving nerves, ducts, and blood vessels, patients benefit from less bruising, reduced discomfort, and superior retention of sensation. These factors are particularly relevant as patient demographics evolve. A growing number of women now seek cosmetic enhancement procedures that do not interfere with active lifestyles or career responsibilities, reinforcing why a “lunch break augmentation” narrative has gained traction around this method.

For surgeons, smaller incisions placed discreetly in the inframammary fold mean that scars are minimized and more easily concealed, aligning with growing consumer demand for procedures that deliver natural aesthetics with minimal visible intervention.

What training and expertise are required to adopt this minimally invasive technique?

Dr. Agullo’s introduction of the method follows his completion of specialized training at Establishment Labs’ global headquarters in Alajuela, Costa Rica. The training program—structured as a surgeon-to-surgeon exchange—emphasizes not only the surgical technique but also patient selection, implant handling, and long-term care.

Establishment Labs has positioned this training as part of its global network strategy, ensuring that surgeons across major markets adopt consistent standards of care. For practitioners like Dr. Agullo, participation in this program signals both clinical expertise and alignment with a global community pushing for safer, more effective augmentation practices.

Market analysts often note that the integration of such training ecosystems with proprietary implant technology strengthens Establishment Labs’ competitive moat. It creates brand loyalty among surgeons while reinforcing the company’s reputation as more than just a device manufacturer—rather, a thought leader in the aesthetic medicine ecosystem.

How does this development fit into broader sector and economic trends?

The global breast implant market, valued at nearly $2.2 billion in 2024, has been shifting toward safer, more technologically advanced solutions. Regulatory scrutiny in the United States and Europe over the past decade has pushed manufacturers to invest heavily in biocompatibility, long-term safety data, and advanced materials. Establishment Labs, in particular, has capitalized on this trend, differentiating itself from competitors by marketing its products as part of a holistic wellness-driven approach rather than as isolated surgical devices.

In the U.S., demand for breast augmentation remains strong, with more than 300,000 procedures performed annually according to the American Society of Plastic Surgeons. However, patient preferences are clearly evolving. A growing percentage now prioritize faster recovery times, minimal scarring, and natural-looking results over sheer volume or dramatic changes. Techniques like Motiva Preservé are strategically positioned to capture this demand shift, particularly among millennials and Gen Z patients who often balance professional obligations with active lifestyles.

From an economic lens, minimally invasive surgeries tend to reduce both direct and indirect costs. Patients spend less time off work, fewer resources are devoted to extended hospital stays, and overall post-surgical care burdens are reduced. For insurers and private clinics, such efficiencies can represent meaningful cost savings.

What is the investor and market sentiment around Establishment Labs’ role in these advancements?

Since Establishment Labs is publicly listed (NASDAQ: ESTA), its financial performance and innovation pipeline are closely tracked by both institutional and retail investors. The company reported revenues of approximately $176 million in 2024, with breast aesthetics accounting for the majority of its portfolio. Analysts frequently cite its strong international footprint and regulatory clearances across multiple regions as reasons for its premium valuation relative to traditional medical device peers.

Market sentiment has generally trended positively around the company’s emphasis on innovation. The rollout of the Motiva Preservé technique in new markets, including through high-profile practitioners such as Dr. Agullo, is perceived as a catalyst for both revenue growth and brand recognition.

Recent trading activity reflects cautious optimism. While the stock has experienced volatility alongside broader medtech equities, institutional flows indicate sustained interest, particularly from funds focused on long-term growth in aesthetic medicine. Buy-side sentiment leans toward “hold with upside potential,” with some analysts suggesting that wider adoption of Preservé could translate into a significant competitive edge by 2026. Retail investors have also expressed interest in ESTA as a niche growth play within the broader health and beauty sector.

What does this development mean for patients and the future of plastic surgery practices?

For patients in El Paso and beyond, the availability of Motiva Preservé breast-preservation augmentation represents more than a cosmetic choice. It signals access to a new philosophy of surgical care, one where natural tissue preservation and rapid recovery are prioritized over traditional, more invasive methods. As Dr. Agullo has emphasized, his goal is to deliver natural enhancement with minimal disruption to daily life—an ethos increasingly echoed across modern plastic surgery.

Looking ahead, industry observers expect that this minimally invasive model will not remain limited to breast augmentation. Techniques that emphasize small incisions, lighter implants, and preserved anatomy may inspire a new wave of surgical innovation across other fields of reconstructive and aesthetic medicine. Establishment Labs’ continued investment in training programs, coupled with strong surgeon adoption, suggests that the company is positioning itself as a central player in this broader transformation.

Southwest Plastic Surgery’s adoption of the Motiva Preservé technique beginning in August 2025 marks a pivotal moment for both local patients and the wider U.S. market. By combining global training, advanced biomaterials, and a philosophy of patient-first care, this development reaffirms the aesthetic medicine sector’s trajectory toward innovation that aligns with lifestyle demands and long-term well-being. For investors, surgeons, and patients alike, it reflects how medical technology and surgical artistry are converging to reshape expectations in modern plastic surgery.